10RCA is developed by Buddhist Tzu Chi General Hospital.

What development phase is 10RCA in?

10RCA is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

10RCA

Buddhist Tzu Chi General Hospital · FDA-approved active Small molecule Quality 4/100

At a glance

Generic name	10RCA
Also known as	Pariet x 10 days, Klaricid x 10 days, Hiconcil x 10 days.
Sponsor	Buddhist Tzu Chi General Hospital
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Comparison Between Ten Days Sequential Treatment and Traditional Three Combined Treatment of Helicobacter Pylori (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

10RCA CI brief — competitive landscape report
10RCA updates RSS · CI watch RSS
Buddhist Tzu Chi General Hospital portfolio CI